<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37835071</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>19</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated &#xdf;2-Adrenergic Receptor Autoantibodies-An Interim Report.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6428</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm12196428</ELocationID><Abstract><AbstractText>There is increasing evidence for an autoimmune aetiology in post-infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). SARS-CoV-2 has now become the main trigger for ME/CFS. We have already conducted two small proof-of-concept studies on IgG depletion by immunoadsorption (IA) in post-infectious ME/CFS, which showed efficacy in most patients. This observational study aims to evaluate the efficacy of IA in patients with post-COVID-19 ME/CFS. The primary objective was to assess the improvement in functional ability. Due to the urgency of finding therapies for post-COVID-Syndrome (PCS), we report here the interim results of the first ten patients, with seven responders defined by an increase of between 10 and 35 points in the Short-Form 36 Physical Function (SF36-PF) at week four after IA. The results of this observational study will provide the basis for patient selection for a randomised controlled trial (RCT), including sham apheresis, and for an RCT combining IA with B-cell depletion therapy. Trial registration number: NCT05629988.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Medical Immunology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heindrich</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Medical Immunology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wittke</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Medical Immunology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kedor</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9361-9213</Identifier><AffiliationInfo><Affiliation>Institute for Medical Immunology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0000-4909-2805</Identifier><AffiliationInfo><Affiliation>Institute for Medical Immunology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freitag</LastName><ForeName>Helma</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5950-0489</Identifier><AffiliationInfo><Affiliation>Institute for Medical Immunology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xfc;ger</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xf6;lle</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9843-2132</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheibenbogen</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8554-9638</Identifier><AffiliationInfo><Affiliation>Institute for Medical Immunology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05629988</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>01EP2201</GrantID><Agency>Federal Ministry of Education and Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GPCR-antibodies</Keyword><Keyword MajorTopicYN="N">Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</Keyword><Keyword MajorTopicYN="N">SF-36</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">immunoadsorption</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">physical function</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome</Keyword></KeywordList><CoiStatement>Charit&#xe9; holds, together with CellTrend, a patent for the diagnostic use of AABs against ADRB2. CS has a consulting agreement with CellTrend. The other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>14</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>14</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>14</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37835071</ArticleId><ArticleId IdType="pmc">PMC10573450</ArticleId><ArticleId IdType="doi">10.3390/jcm12196428</ArticleId><ArticleId IdType="pii">jcm12196428</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., on behalf of the WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Premraj L., Kannapadi N.V., Briggs J., Seal S.M., Battaglini D., Fanning J., Suen J., Robba C., Fraser J., Cho S.M. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. J. Neurol. Sci. 2022;434:120162. doi: 10.1016/j.jns.2022.120162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120162</ArticleId><ArticleId IdType="pmc">PMC8798975</ArticleId><ArticleId IdType="pubmed">35121209</ArticleId></ArticleIdList></Reference><Reference><Citation>Legler F., Meyer-Arndt L., M&#xf6;dl L., Kedor C., Freitag H., Stein E., Hoppmann U., Rust R., Wittke K., Siebert N., et al. Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: Results from a prospective observational cohort. eClinicalMedicine. 2023;63:102146. doi: 10.1016/j.eclinm.2023.102146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102146</ArticleId><ArticleId IdType="pmc">PMC10469383</ArticleId><ArticleId IdType="pubmed">37662515</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman C.S., Bhatia S., Cotler J., Jason L.A. Assessment of Post-Exertional Malaise (PEM) in Patients with Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS): A Patient-Driven Survey. Diagnostics. 2019;9:26. doi: 10.3390/diagnostics9010026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics9010026</ArticleId><ArticleId IdType="pmc">PMC6468435</ArticleId><ArticleId IdType="pubmed">30832336</ArticleId></ArticleIdList></Reference><Reference><Citation>Deumer U.S., Varesi A., Floris V., Savioli G., Mantovani E., Lopez-Carrasco P., Rosati G.M., Prasad S., Ricevuti G. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview. J. Clin. Med. 2021;10:4786. doi: 10.3390/jcm10204786.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10204786</ArticleId><ArticleId IdType="pmc">PMC8538807</ArticleId><ArticleId IdType="pubmed">34682909</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukocheva O.A., Maksoud R., Beeraka N.M., Madhunapantula S.V., Sinelnikov M., Nikolenko V.N., Neganova M.E., Klochkov S.G., Amjad Kamal M., Staines D.R., et al. Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome. J. Adv. Res. 2022;40:179&#x2013;196. doi: 10.1016/j.jare.2021.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jare.2021.11.013</ArticleId><ArticleId IdType="pmc">PMC8619886</ArticleId><ArticleId IdType="pubmed">36100326</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph P., Singh I., Oliveira R., Capone C.A., Mullen M.P., Cook D.B., Stovall M.C., Squires J., Madsen K., Waxman A.B., et al. Exercise Pathophysiology in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Postacute Sequelae of SARS-CoV-2: More in Common Than Not? Chest. 2023;164:717&#x2013;726. doi: 10.1016/j.chest.2023.03.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2023.03.049</ArticleId><ArticleId IdType="pmc">PMC10088277</ArticleId><ArticleId IdType="pubmed">37054777</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner S., Khan M.A., Putrino D., Woodcock A., Kell D.B., Pretorius E. Long COVID: Pathophysiological factors and abnormalities of coagulation. Trends Endocrinol. Metab. 2023;34:321&#x2013;344. doi: 10.1016/j.tem.2023.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2023.03.002</ArticleId><ArticleId IdType="pmc">PMC10113134</ArticleId><ArticleId IdType="pubmed">37080828</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J.M., Herran M., Beltran S., Rojas M. Is post-COVID syndrome an autoimmune disease? Expert. Rev. Clin. Immunol. 2022;18:653&#x2013;666. doi: 10.1080/1744666X.2022.2085561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2085561</ArticleId><ArticleId IdType="pubmed">35658801</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.Y., Mao T., Klein J., Dai Y., Huck J.D., Jaycox J.R., Liu F., Zhou T., Israelow B., Wong P., et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283&#x2013;288. doi: 10.1038/s41586-021-03631-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Szewczykowski C., Mardin C., Lucio M., Wallukat G., Hoffmanns J., Schroder T., Raith F., Rogge L., Heltmann F., Moritz M., et al. Long COVID: Association of Functional Autoantibodies against G-Protein-Coupled Receptors with an Impaired Retinal Microcirculation. Int. J. Mol. Sci. 2022;23:7209. doi: 10.3390/ijms23137209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23137209</ArticleId><ArticleId IdType="pmc">PMC9266742</ArticleId><ArticleId IdType="pubmed">35806214</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotzny F., Filgueiras I.S., Kedor C., Freitag H., Wittke K., Bauer S., Sepulveda N., Mathias da Fonseca D.L., Baiocchi G.C., Marques A.H.C., et al. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front. Immunol. 2022;13:981532. doi: 10.3389/fimmu.2022.981532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.981532</ArticleId><ArticleId IdType="pmc">PMC9552223</ArticleId><ArticleId IdType="pubmed">36238301</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii H., Sato W., Kimura Y., Matsuda H., Ota M., Maikusa N., Suzuki F., Amano K., Shin I., Yamamura T., et al. Altered Structural Brain Networks Related to Adrenergic/Muscarinic Receptor Autoantibodies in Chronic Fatigue Syndrome. J. Neuroimaging. 2020;30:822&#x2013;827. doi: 10.1111/jon.12751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jon.12751</ArticleId><ArticleId IdType="pubmed">32609410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura Y., Sato W., Maikusa N., Ota M., Shigemoto Y., Chiba E., Arizono E., Maki H., Shin I., Amano K., et al. Free-water-corrected diffusion and adrenergic/muscarinic antibodies in myalgic encephalomyelitis/chronic fatigue syndrome. J. Neuroimaging. 2023;33:845&#x2013;851. doi: 10.1111/jon.13128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jon.13128</ArticleId><ArticleId IdType="pubmed">37243973</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravelsina S., Vilmane A., Svirskis S., Rasa-Dzelzkaleja S., Nora-Krukle Z., Vecvagare K., Krumina A., Leineman I., Shoenfeld Y., Murovska M. Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome. Front. Immunol. 2022;13:928945. doi: 10.3389/fimmu.2022.928945.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.928945</ArticleId><ArticleId IdType="pmc">PMC9589447</ArticleId><ArticleId IdType="pubmed">36300129</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibenbogen C., Loebel M., Freitag H., Krueger A., Bauer S., Antelmann M., Doehner W., Scherbakov N., Heidecke H., Reinke P., et al. Immunoadsorption to remove ss2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS ONE. 2018;13:e0193672. doi: 10.1371/journal.pone.0193672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0193672</ArticleId><ArticleId IdType="pmc">PMC5854315</ArticleId><ArticleId IdType="pubmed">29543914</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., David P., Arnheim D., Shoenfeld Y. The autonomic aspects of the post-COVID19 syndrome. Autoimmun. Rev. 2022;21:103071. doi: 10.1016/j.autrev.2022.103071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2022.103071</ArticleId><ArticleId IdType="pmc">PMC8848724</ArticleId><ArticleId IdType="pubmed">35182777</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Lipkin W.I. ME/CFS and Long COVID share similar symptoms and biological abnormalities: Road map to the literature. Front. Med. 2023;10:1187163. doi: 10.3389/fmed.2023.1187163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1187163</ArticleId><ArticleId IdType="pmc">PMC10278546</ArticleId><ArticleId IdType="pubmed">37342500</ArticleId></ArticleIdList></Reference><Reference><Citation>Koll R.A. Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins. Ther. Apher. 1998;2:147&#x2013;152. doi: 10.1111/j.1744-9987.1998.tb00093.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1744-9987.1998.tb00093.x</ArticleId><ArticleId IdType="pubmed">10225717</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs K., Rummler S., Ries W., Helmschrott M., Selbach J., Ernst F., Morath C., Gauly A., Atiye S., Stauss-Grabo M., et al. Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications. Ther. Apher. Dial. 2022;26:229&#x2013;241. doi: 10.1111/1744-9987.13663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1744-9987.13663</ArticleId><ArticleId IdType="pmc">PMC9291474</ArticleId><ArticleId IdType="pubmed">33914397</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibenbogen C., Bellmann-Strobl J.T., Heindrich C., Wittke K., Stein E., Franke C., Pruss H., Pressler H., Machule M.L., Audebert H., et al. Fighting Post-COVID and ME/CFS-development of curative therapies. Front. Med. 2023;10:1194754. doi: 10.3389/fmed.2023.1194754.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1194754</ArticleId><ArticleId IdType="pmc">PMC10309204</ArticleId><ArticleId IdType="pubmed">37396922</ArticleId></ArticleIdList></Reference><Reference><Citation>Brigden A., Parslow R.M., Gaunt D., Collin S.M., Jones A., Crawley E. Defining the minimally clinically important difference of the SF-36 physical function subscale for paediatric CFS/ME: Triangulation using three different methods. Health Qual. Life Outcomes. 2018;16:202. doi: 10.1186/s12955-018-1028-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-018-1028-2</ArticleId><ArticleId IdType="pmc">PMC6194701</ArticleId><ArticleId IdType="pubmed">30340599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotler J., Holtzman C., Dudun C., Jason L.A. A Brief Questionnaire to Assess Post-Exertional Malaise. Diagnostics. 2018;8:66. doi: 10.3390/diagnostics8030066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics8030066</ArticleId><ArticleId IdType="pmc">PMC6165517</ArticleId><ArticleId IdType="pubmed">30208578</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitag H., Szklarski M., Lorenz S., Sotzny F., Bauer S., Philippe A., Kedor C., Grabowski P., Lange T., Riemekasten G., et al. Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. J. Clin. Med. 2021;10:3675. doi: 10.3390/jcm10163675.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10163675</ArticleId><ArticleId IdType="pmc">PMC8397061</ArticleId><ArticleId IdType="pubmed">34441971</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap)&#x2014;A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 2009;42:377&#x2013;381. doi: 10.1016/j.jbi.2008.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2008.08.010</ArticleId><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris P.A., Taylor R., Minor B.L., Elliott V., Fernandez M., O&#x2019;Neal L., McLeod L., Delacqua G., Delacqua F., Kirby J., et al. The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103208</ArticleId><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Blish C.A., Sallusto F., Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375:1122&#x2013;1127. doi: 10.1126/science.abm8108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D., Chalon P., Kohn L., Dauvrin M., Detollenaere J., Maertens de Noordhout C., Primus-de Jong C., Cleemput I., Van den Heede K. Pathophysiology and mechanism of long COVID: A comprehensive review. Ann. Med. 2022;54:1473&#x2013;1487. doi: 10.1080/07853890.2022.2076901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaunt D., Brigden A., Metcalfe C., Loades M., Crawley E. Investigating the factors associated with meaningful improvement on the SF-36-PFS and exploring the appropriateness of this measure for young people with ME/CFS accessing an NHS specialist service: A prospective cohort study. BMJ Open. 2023;13:e069110. doi: 10.1136/bmjopen-2022-069110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-069110</ArticleId><ArticleId IdType="pmc">PMC10450087</ArticleId><ArticleId IdType="pubmed">37620254</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragun D., Philippe A., Catar R., Hegner B. Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. Thromb. Haemost. 2009;101:643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">19350106</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemekasten G., Petersen F., Heidecke H. What Makes Antibodies Against G Protein-Coupled Receptors so Special? A Novel Concept to Understand Chronic Diseases. Front. Immunol. 2020;11:564526. doi: 10.3389/fimmu.2020.564526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.564526</ArticleId><ArticleId IdType="pmc">PMC7770155</ArticleId><ArticleId IdType="pubmed">33384684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartwig J., Sotzny F., Bauer S., Heidecke H., Riemekasten G., Dragun D., Meisel C., Dames C., Grabowski P., Scheibenbogen C. IgG stimulated beta2 adrenergic receptor activation is attenuated in patients with ME/CFS. Brain Behav. Immun. Health. 2020;3:100047. doi: 10.1016/j.bbih.2020.100047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2020.100047</ArticleId><ArticleId IdType="pmc">PMC8474590</ArticleId><ArticleId IdType="pubmed">34589837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremonesi M., Felicetta A., Cannata F., Serio S., van Beek J.J.P., Bombace S., My I., Zanon V., Catalano C., Papadopoulou V., et al. Long COVID-19 Cardiac Complications Are Associated With Autoimmunity to Cardiac Self-Antigens Sufficient to Cause Cardiac Dysfunction. Circulation. 2023;148:504&#x2013;507. doi: 10.1161/CIRCULATIONAHA.122.062672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.062672</ArticleId><ArticleId IdType="pubmed">37549204</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou A.G., Vrettou C.S., Keskinidou C., Dimopoulou I., Kotanidou A., Orfanos S.E. Endotheliopathy in Acute COVID-19 and Long COVID. Int. J. Mol. Sci. 2023;24:8237. doi: 10.3390/ijms24098237.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24098237</ArticleId><ArticleId IdType="pmc">PMC10179170</ArticleId><ArticleId IdType="pubmed">37175942</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Appelman B., Mooij-Kalverda K., Houtkooper R.H., van Weeghel M., Vaz F.M., Dijkhuis A., Dekker T., Smids B.S., Duitman J.W., et al. Prolonged indoleamine 2,3-dioxygenase-2 activity and associated cellular stress in post-acute sequelae of SARS-CoV-2 infection. EBioMedicine. 2023;94:104729. doi: 10.1016/j.ebiom.2023.104729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104729</ArticleId><ArticleId IdType="pmc">PMC10406961</ArticleId><ArticleId IdType="pubmed">37506544</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Ryder D., Flavell R., Wang Y., Levi J., LaFranchi B.H., Deveau T.M., Buck A.M., Munter S.E., Asare K.A., et al. Multimodal Molecular Imaging Reveals Tissue-Based T Cell Activation and Viral RNA Persistence for Up to 2 Years Following COVID-19. medRxiv. 2023 doi: 10.1101/2023.07.27.23293177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.07.27.23293177</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>